image header

News Releases

News Releases

Oct 14, 2020

ALX Oncology to Present ALX148 Clinical Data at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting Read more

Oct 6, 2020

ALX Oncology Names Leading Oncology Experts to Scientific Advisory Board Read more

Sep 22, 2020

ALX Oncology to Collaborate with Merck on Phase 2 Immuno-Oncology Studies Evaluating ALX148, Targeting CD47, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Head & Neck Cancer Read more

Sep 17, 2020

ALX Oncology Added to Russell 2000® and 3000® Indexes Read more

Sep 8, 2020

ALX Oncology Announces Participation at Upcoming Investor Conferences Read more

Aug 27, 2020

ALX Oncology Reports Second Quarter 2020 Financial Results and Provides Operational and Clinical Highlights Read more

Jul 21, 2020

ALX Oncology Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares Read more

Jul 16, 2020

ALX Oncology Announces Pricing of Initial Public Offering Read more

Jun 12, 2020

ALX Oncology Presents Preliminary Phase 1 Study Results of ALX148 in Combination with Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Read more

May 29, 2020

ALX Oncology Presents Phase 1 Study Results of ALX148 in Combination with Standard Anti-Cancer Antibodies and Chemotherapy Regimens in Patients with Advanced Solid Tumors Read more

Displaying 1 - 10 of 16